A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Purpose: In vitro data showed that selexipag and its active metabolite (ACT-333679) have an inductive effect on CYP3A4, CYP2B6, and CYP2C9 at concentrations approximately 100-fold higher than the maximum plasma concentration ( C ) measured under steady-state conditions. In order to confirm in vivo t...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 73; no. 9; pp. 1121 - 1129 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Sep2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |